Medication info
Nesinamet Tablets 12.5/500 mg (Alogliptin Benzoate, Metformin Hydrochloride)

Nesinamet Tablets 12.5/500 mg (Alogliptin Benzoate, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Alogliptin Benzoate›17mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Celltrion Pharm, Co., Ltd.
Appearance
Light yellow rectangular film-coated tablets
Packaging
PTP - 28 tablets/Alu-Alu[(7 X 4)], Bottle - 30 tablets/bottle[(Bottle-HDPE, Cap-PP, Silica Gel)], Bottle - 100 tablets/bottle[(Bottle-HDPE, Cap-PP, Silica Gel)]
Approval status
Active

MFDS item code 202303459 · Approved 2023.12.28 · Insurance code 693903840

Summary

Main use
Improves blood glucose control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medicine should be adjusted according to efficacy and tolerability, without exceeding the maximum recommended daily doses of each component: alogliptin 25mg and metformin 2000mg. The initial dose of this medicine is determined based on the patient's current treatment regimen. This medicine should be taken twice daily with meals, and the dose should be increased gradually to reduce gastrointestinal adverse reactions associated with metformin use. This medicine should be swallowed whole. 1. Patients not currently treated with metformin The initial dose is 1 tablet of this medicine 12.5/500mg twice daily. The dose may be increased to 1 tablet of this medicine 12.5/1000mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy The initial dose of this medicine should be based on the patient's current treatment regimen and consist of alogliptin 12.5mg twice daily (total daily dose 25mg) and the patient's current metformin dose. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and pioglitazone The initial dose is alogliptin 12.5mg twice daily (total daily dose 25mg). The initial metformin dose should take into account the patient's blood glucose level and current dose. 4. Patients unable to achieve adequate glycemic control with combination therapy of metformin and insulin The initial dose is alogliptin 12.5mg twice daily (total daily dose 25mg). The initial metformin dose should take into account the patient's blood glucose level and current dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. 5. Substitution for combination therapy with alogliptin and metformin When switching from combination therapy with alogliptin and metformin to this medicine, treatment may be initiated at the patient's current doses of alogliptin and metformin.

Ingredients

Manufacturer
Celltrion Pharm, Co., Ltd.

Efficacy & effects

Improves blood glucose control in patients with type 2 diabetes

View approved original text

This medication is developed to help control blood sugar in patients with type 2 diabetes. The two components, Alogliptin and Metformin, work together to complement dietary and exercise therapies. It is particularly effective in improving blood sugar levels, making it suitable for those who struggle with blood sugar management. Continued usage along with lifestyle changes can yield even better results. This medication is used for the treatment of type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be adjusted according to efficacy and tolerability, without exceeding the maximum recommended daily doses of each component: alogliptin 25mg and metformin 2000mg. The initial dose of this medicine is determined based on the patient's current treatment regimen. This medicine should be taken twice daily with meals, and the dose should be increased gradually to reduce gastrointestinal adverse reactions associated with metformin use. This medicine should be swallowed whole. 1. Patients not currently treated with metformin The initial dose is 1 tablet of this medicine 12.5/500mg twice daily. The dose may be increased to 1 tablet of this medicine 12.5/1000mg twice daily. 2. Patients unable to achieve adequate glycemic control with metformin monotherapy The initial dose of this medicine should be based on the patient's current treatment regimen and consist of alogliptin 12.5mg twice daily (total daily dose 25mg) and the patient's current metformin dose. 3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and pioglitazone The initial dose is alogliptin 12.5mg twice daily (total daily dose 25mg). The initial metformin dose should take into account the patient's blood glucose level and current dose. 4. Patients unable to achieve adequate glycemic control with combination therapy of metformin and insulin The initial dose is alogliptin 12.5mg twice daily (total daily dose 25mg). The initial metformin dose should take into account the patient's blood glucose level and current dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. 5. Substitution for combination therapy with alogliptin and metformin When switching from combination therapy with alogliptin and metformin to this medicine, treatment may be initiated at the patient's current doses of alogliptin and metformin.

Precautions

This medication may cause severe lactic acidosis or hypoglycemia; caution is required. It should not be administered to patients with moderate to severe renal impairment or cardiovascular diseases. Patients undergoing surgeries or diagnostic tests involving radiological contrast agents should discontinue this medication for a certain period and only resume after confirming normal kidney function. It is advisable for pregnant or breastfeeding women to refrain from taking this medication. Patients with irregular meals or engaging in intense physical activities, or those taking other medications simultaneously, should be careful as they may be at risk for hypoglycemia and lactic acidosis. While taking this medication, side effects such as diarrhea, headache, back pain, and infections may occur, and if symptoms persist, consultation with a physician is necessary. Although rare, lactic acidosis can be life-threatening; therefore, if symptoms such as malaise, muscle pain, difficulty breathing, or abdominal pain arise, medical attention should be sought immediately. If symptoms indicating liver dysfunction or pancreatitis are suspected, discontinue the medication and visit a hospital promptly. Since this medication is excreted through the kidneys, regular kidney function tests should be conducted in patients with reduced renal function, and administration should cease if kidney function deteriorates. Alcohol can increase the risk of lactic acidosis, so it is advisable to avoid drinking while on this medication. Additionally, this medication may lower vitamin B12 levels; therefore, regular blood tests should be performed, and supplementation should be provided as needed. When combined with other hypoglycemic agents, there may be an increased risk of hypoglycemia, so blood glucose levels should be closely monitored, and dose adjustments may be necessary.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • upper respiratory tract infection
  • nasopharyngitis
  • diarrhea
  • hypertension
  • headache
  • low back pain
  • urinary tract infection
  • pancreatitis
Show 183 more
  • hypersensitivity reaction
  • serum sickness
  • nausea
  • vomiting
  • abdominal distension
  • asthenia
  • dyspepsia
  • abdominal discomfort
  • acute renal failure
  • cirrhosis
  • cholelithiasis
  • chest discomfort
  • generalized edema
  • systemic weakness
  • dyspnea
  • exacerbation of asthma
  • exacerbation of pneumonia
  • apnea
  • nephrolithiasis
  • renal dysfunction
  • hematuria
  • abnormal liver function tests
  • abscess
  • infection
  • wound dehiscence
  • herpes labialis
  • herpes simplex virus infection
  • benign prostatic hyperplasia
  • loss of appetite
  • depression
  • hypersensitivity
  • erectile dysfunction
  • insomnia
  • sleep disorders
  • orthostatic hypotension
  • hypotension
  • tinnitus
  • acute hearing loss
  • Meniere's disease
  • thyroid carcinoma
  • lung cancer
  • coronary artery occlusion
  • myocardial infarction
  • angina pectoris
  • bradycardia
  • palpitations
  • exacerbation of atrial fibrillation
  • cerebral infarction
  • transient ischemic attack
  • hypothyroidism
  • nodular goiter
  • chest pain
  • back pain
  • speech disorder
  • paresthesia
  • sensory disturbance
  • femoral sensory disturbance syndrome
  • fecal incontinence
  • tremor
  • numbness
  • neuropathic pain
  • spinal canal stenosis
  • hemiparesis
  • skin sensory disturbance
  • dizziness
  • lightheadedness
  • vertigo
  • ligament injury
  • rib fracture
  • tendinitis
  • fracture
  • joint pain
  • fibromyalgia
  • muscle cramps
  • myalgia
  • costochondritis
  • leg fracture
  • lower limb weakness syndrome
  • malaise
  • trigger finger syndrome
  • upper extremity fracture
  • plantar fasciitis
  • spinal fracture
  • rhabdomyolysis
  • tendon rupture
  • arthropathy
  • lower limb weakness syndrome
  • malaise
  • pruritus
  • contact dermatitis
  • itching
  • keratosis
  • sclerosis
  • increased sweating
  • nail disease
  • otitis externa
  • pityriasis rosea
  • rosacea
  • contact dermatitis
  • furunculosis
  • seborrheic dermatitis
  • conjunctivitis
  • glaucoma
  • macular degeneration
  • cataract
  • keratitis
  • retinal disease
  • retinal disorder
  • urinary bladder inflammation
  • exacerbation of cystitis
  • frequent urination
  • neurogenic bladder
  • renal cyst
  • urethritis
  • increased serum creatinine
  • biliary sclerosis
  • hepatic steatosis
  • increased AST
  • increased ALT
  • herpes zoster
  • severe and disabling joint pain
  • vesiculobullous pemphigoid
  • chest discomfort
  • pelvic pain
  • leg edema
  • exacerbation of back pain
  • sacroiliac pain
  • pain
  • arm swelling
  • exacerbation of chest pain
  • fever
  • edema
  • skin cyst
  • neck/shoulder pain
  • pharyngitis
  • cough
  • increased sputum
  • bronchospasm
  • dry cough
  • chronic obstructive pulmonary disease
  • throat irritation
  • sinusitis
  • shortness of breath
  • sore throat
  • tonsillitis
  • pneumonia
  • increased blood sugar
  • hyperlipidemia
  • diabetes complications
  • dyslipidemia
  • increased triglycerides
  • vitamin D deficiency
  • increased triglycerides
  • increased CPK
  • hyperkalemia
  • acidosis
  • dry eye syndrome
  • gout
  • increased blood sugar levels
  • pruritus
  • lack of effect
  • systemic weakness
  • leg pain
  • lower abdominal pain
  • constipation
  • exacerbation of gastritis
  • gastroesophageal reflux
  • heartburn
  • stomatitis
  • abdominal pain
  • gastroesophageal reflux disease
  • gastric disorder
  • atrophic gastritis
  • epigastric pain unrelated to food
  • enteritis
  • periodontitis
  • toothache
  • belching
  • anal fissure
  • bloody stools
  • black stools
  • orthostatic hypotension
  • hypotension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. The storage temperature should be maintained between 1 to 30 degrees Celsius at room temperature. Proper storage can ensure the medication's effectiveness and safety over time.

Appearance and packaging

Appearance

Light yellow rectangular film-coated tablets

Package unit

PTP - 28 tablets/Alu-Alu[(7 X 4)], Bottle - 30 tablets/bottle[(Bottle-HDPE, Cap-PP, Silica Gel)], Bottle - 100 tablets/bottle[(Bottle-HDPE, Cap-PP, Silica Gel)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.